<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419470</url>
  </required_header>
  <id_info>
    <org_study_id>YCD173</org_study_id>
    <nct_id>NCT01419470</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044</brief_title>
  <official_title>Phase Ⅰ/Ⅱ Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 After Oral Administration in Premature Ejaculation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      safety and tolerability, pharmacokinetics/efficacy of an escalating, repeat doses of YHD1044
      in premature ejaculation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>throughout the study up to day 28</time_frame>
    <description>through physical examination, laboratory result, vital sign,ECG etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy(IELT)</measure>
    <time_frame>13days, 28days</time_frame>
    <description>change from baseline in IELT at the Day 13, 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax(Cmax,ss), Cmin,ss, AUCinf, AUCt, Tmax, CL/F</measure>
    <time_frame>specified timepoints in the protocol</time_frame>
    <description>Cmax(Cmax,ss), Cmin,ss, AUCinf, AUCt will be assessed. Samping time point: intensive sampling(Day1~2, Day14~15)&amp; intermittent sampling(Day3~Day 28 except intensive sampling period)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Premature Ejaculation</condition>
  <arm_group>
    <arm_group_label>YHD1044 I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YHD1044 III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>YHD1044 V</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapoxetine</intervention_name>
    <description>multiple dosing
12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine</description>
    <arm_group_label>YHD1044 I</arm_group_label>
    <arm_group_label>YHD1044 III</arm_group_label>
    <arm_group_label>YHD1044 V</arm_group_label>
    <other_name>Priligy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is in a stable, monogamous sexual relationship with the same woman for at
             least 6 months and plans to maintain this relationship for the duration of the study

          -  History of premature ejaculation in the 6 months before study initiation

          -  History of intravaginal ejaculatory latency time (IELT) of &lt; = 2 minutes in at least
             half of events

          -  Premature Ejaculation Diagnostic Tool (PEDT) &gt; =11

          -  6 domains of International Index of Erectile Function(IIEF) &gt;= 21

          -  Patient and partner must agree to attempt sexual intercourse at minimum intervals
             specified in the protocol

          -  Patient's partner must have a negative urine pregnancy test at time of screening

        Exclusion Criteria:

          -  Medical history which affects ADME in the past 3 years

          -  Clinically significant and active disorder in ophthalmic system, gastro-intestine,
             cardiovascular, respiratory system, endocrine system, autoimmune system or malignant
             tumor,

          -  Subjects with clinically significant observations considered as unsuitable based on
             medical judgment in the physical examination and clinical laboratory tests or a
             medical history

          -  History of psychological disease

          -  Clinically significant allergic disease

          -  Hypersensitivity to TCA, SSRIs(Clomipramine, sertraline, fluoxetine, dapoxetine)

          -  Taken dapoxetine within 3 months

          -  Using other forms of therapy for treatment of PE (behavioral therapy or medications
             applied to the skin)

          -  Taken another investigational drug within 1 month

          -  History of drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>July 31, 2012</last_update_submitted>
  <last_update_submitted_qc>July 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Premature Ejaculation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

